Condition: Multiple Myeloma · Sponsor: AbbVie
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; phase 2 with 3 study arms and phase 3 with 2 study arms. Participants in phase 2 will receive 1 of 3 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive etentamig at RP3D in combination with daratumumab, or daratumumab, lenalidomide, and dexamethasone (DRd). Around 660 adult participants with MM will be enrolled at approximately 155 sites worldwide Participants in phase 2 will receive 1 of 3 doses of etentamig as intravenous (IV) infusions, combination with subcutaneous (SC) injections of daratumumab. Participants in phase 3 will receive RP3D doses of etentamig as IV infusions, combination with SC injections of daratumumab, or SC injections of daratumumab, capsules of lenalidomide, and tablet/ IV injections of dexamethasone (DRd). The study duration is approximately 16 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospita…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital Scottsdale /ID# 278349 | Scottsdale, Arizona, United States | Recruiting |
| Cedars-Sinai Medical Center /ID# 278238 | Los Angeles, California, United States | Recruiting |
| Colorado Blood Cancer Institute /ID# 279080 | Denver, Colorado, United States | Recruiting |
| Winship Cancer Institute of Emory University /ID# 277667 | Atlanta, Georgia, United States | Recruiting |
| Fort Wayne Medical Oncology And Hematology /ID# 278141 | Fort Wayne, Indiana, United States | Recruiting |
| Minnesota Oncology - Minneapolis Clinic /ID# 278720 | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic Hospital Rochester /ID# 277886 | Rochester, Minnesota, United States | Recruiting |
| Icahn School of Medicine at Mount Sinai /ID# 277844 | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946 | New York, New York, United States | Recruiting |
| Weill Cornell Medicine Myeloma Center /ID# 278216 | New York, New York, United States | Recruiting |
| University of North Carolina at Chapel Hill /ID# 277708 | Chapel Hill, North Carolina, United States | Recruiting |
| Willamette Valley Cancer Institute and Research Center /ID# 278721 | Eugene, Oregon, United States | Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07095452